Assessment of Thrombotic Status in Patients at Risk of Cardiovascular Thrombosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with coronary artery disease (CAD) and atrial fibrillation (AF) are at increased risk of stroke and heart attack. Such events are usually caused by increased stickiness of the blood causing a blood clot to block the artery (thrombus) in the heart or the brain. The aim of this study is to assess the stickiness of the blood (global thrombotic status) in patients with CAD and AF at baseline and after clinical stabilisation to see how disease state and clinical treatments affect the stickiness of the blood (thrombotic status). This will be a single centre study. Patients diagnosed with CAD or AF will have a blood sample taken at baseline and after clinical stabilisation. Blood stickiness will be tested with the Global Thrombosis Test. The results will be evaluated to assess the effect of disease process and clinical state on blood stickiness to gain further understanding of this condition and form the basis for future studies aimed at identifying patients who are at high risk of future cardiovascular events, based on increased blood stickiness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stroke Risk in the NAS-NRC Twin Registry

NCT00005413

Cardiovascular Diseases Cerebrovascular Accident Myocardial Infarction +1 more

COMPLETED

The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function

NCT04043026

Atrial Fibrillation Chronic Kidney Disease

TERMINATED

Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease

NCT06126367

Atherosclerosis Aortic Valve Disease

RECRUITING

Thrombogenic Factors and Recurrent Coronary Events

NCT00005358

Cardiovascular Diseases Heart Diseases Coronary Disease +3 more

COMPLETED

Novel Hemostatic Cardiac Risk Factors in Framingham

NCT00005356

Cardiovascular Diseases Heart Diseases Death, Sudden, Cardiac +4 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Impaired thrombotic status is associated with adverse cardiovascular events. Patients with coronary artery disease (CAD) and atrial fibrillation (AF) are at increased risk of thrombotic events. It is not known whether thrombotic status differs in these patients, or how thrombotic status alters in response to clinical stabilisation with treatment.

The aim of this study is to assess the global thrombotic status (stickiness of the blood) in patients with coronary artery disease and atrial fibrillation at baseline and after clinical stabilisation.

This is a small, pilot, hypothesis-generating study. Design Single centre, hypothesis-generating study. Patients diagnosed with coronary disease (n=70) or atrial fibrillation (n=70) recruited from amongst in-patients or out-patients, will have a blood draw at presentation and after clinical stabilisation. Blood will be tested to assess global thrombotic status.

The recruitment period is 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Patients diagnosed with coronary disease or atrial fibrillation. All the patients will undergo Global Thrombosis Test.

Blood test

Intervention Type DIAGNOSTIC_TEST

Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood test

Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female participants aged 18 years or over.

Exclusion Criteria

3. Not actively using tobacco products (due to vasoactive and pro-aggregatory effects of nicotine).
4. The participant is willing and able to understand the Subject Information Sheet and provide informed consent.
5. The participant must agree to comply with the drawing of blood samples for the assessments.

1. Male and female participants aged \< 18 years of age.
2. Patients with impaired renal function eGFR \<30 ml/min (since renal failure is associated with platelet function defect that may confound results).
3. The participant has, in the opinion of the investigator, significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, haemorrhagic metabolic or other disease likely to confound the study requirements or analyses.
4. The participant has a gives a history of substance abuse or demonstrates signs or clinical features of active substance abuse or psychiatric disease.
5. Alcohol consumption above recommended safe levels (i.e. more than 21 units per week for males, or more than 14 units per week for females) due to the potential effects of high alcohol levels on platelet reactivity.
6. Any illness deemed significant by the investigator during the four (4) weeks preceding the screening period of the study.
7. Any major bleeding diathesis or blood dyscrasia (platelets \< 70 x 109/l, Hb \<8 g/dl, INR\>1.4, APTT\> x 2UNL, leucocyte count\< 3.5x 109/l, neutrophil count \< 1x 109/l)
8. Currently enrolled in an investigational device or drug trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No